PharmaCyte Biotech : Presentation of PharmaCyte Biotech

Published: 2021-09-29 09:02:10 ET PMCB

Safe Harbor Statement and Disclaimer

2

Safe Harbor Statement and Disclaimer (cont'd)

3

Platform Technology for Cancer and Diabetes

Encapsulate Genetically Modified Live Cells to Treat Diseases

concentrations of glucose in the body are employed

4

Pipeline

Pancreatic Cancer:

Encapsulated live cells converting

Preclinical

Phase 1

Phase 2b

Phase 3

Ifosfamide - antitumor effectiveness

and good quality of life*

Ascites Fluid Accumulation:

Encapsulated live cells converting

Preclinical

Phase 1

Phase 2

Phase 3

Ifosfamide - delaying malignant ascites

fluid accumulation

Diabetes:

Encapsulated live cells producing

Preclinical

Phase 1

Phase 2

Phase 3

insulin on demand for Type 1 and

Type 2 diabetes

Cancer Using Cannabinoids:

Encapsulated live cells converting

Preclinical

Phase 1

Phase 2

Phase 3

cannabinoid prodrugs - antitumor

effectiveness and pain control

5

*Our planned Phase 2b clinical trial has been placed clinical hold by the FDA, subject to PharmaCyte satisfying the FDA's concerns. The dark blue

shading indicates the current status of the Company's development program.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

PharmaCyte Biotech Inc. published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 13:01:01 UTC.